Equity Profile

PBH

Prestige Consumer Healthcare Inc.

Health CarePharmaceuticals$2.3B

Aug6Thu

Pre-Earnings Brief

UpcomingQ1-2027After Close5:00 PM EDT

Company Snapshot

Prestige Consumer Healthcare Inc. (PBH) operates in the health care sector, focusing on over-the-counter pharmaceuticals and consumer health products....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing costs and generating income.

Expecting $1.10

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market share and product offerings.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PBH Q1-2027 Earnings Preview

Context

Company Snapshot

Prestige Consumer Healthcare Inc. (PBH) operates in the health care sector, focusing on over-the-counter pharmaceuticals and consumer health products. The company plays a vital role in providing accessible health solutions, which is increasingly important as consumers prioritize health and wellness.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.03%

Avg Stock Reaction

+2.05%

Last Quarter Recap

In Q4-2026, Prestige reported an EPS of $1.23, which was below analyst expectations. The stock reacted positively, increasing by 2.78% the following day despite the earnings miss.

Management Promises & Guidance

Focus on improving product lines and expanding market presence.
Commitment to cost management and operational efficiency.
Plans to enhance marketing strategies for better consumer engagement.

Expectations

Wall Street Expectations

Overall, Wall Street is cautiously optimistic about PBH's upcoming earnings, given the company's historical performance and market conditions.

Bull Case

If PBH beats EPS estimates and shows strong revenue growth, it could signal a recovery and renewed investor confidence, leading to a significant stock price increase.

Bear Case

Conversely, if the company misses expectations again, it may raise concerns about its operational efficiency and market competitiveness, potentially leading to a decline in stock value.

Key Metrics to Watch

Earnings Per Share (EPS)

Expecting $1.10

EPS is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue Growth

Not available

Revenue growth is crucial for assessing the company's ability to expand its market share and product offerings.

Market Share in OTC Products

Not available

Understanding market share will help gauge the company's competitive position in the health care market.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed $1.10 this quarter?

A strong EPS could indicate improved profitability and operational efficiency, which the market will closely watch.

What is the company's strategy for increasing market share in the OTC segment?

Insights into market share strategies will help investors assess the company's competitive position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate PBH's ability to adapt and innovate in the competitive OTC market, potentially leading to a stronger-than-expected performance.

Supporting Evidence

The company's recent investments in marketing and product development could yield better results than anticipated.

Historical data shows that PBH has a 63% EPS beat rate, suggesting a higher likelihood of positive surprises.

Options pricing indicates a significant expected move, which may reflect investor confidence in a turnaround.

Key Risk

If EPS comes in above $1.10, it could challenge the current cautious sentiment and validate the company's recovery narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a series of mixed earnings results, and the market is looking for signs of recovery.

Bull Confirmed If

An EPS of $1.10 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $1.00 would support the bear case, raising concerns about operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±12.18%

Historical Avg

±5.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±12.2% while PBH has averaged ±5.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

45.3%

Calls (0)P/C Ratio: 1.50Puts (10K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If PBH beats expectations, history suggests the stock could rise by an average of 5.17%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of around 3.16%, reflecting ongoing concerns about the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the OTC segment.
2Management's commentary on cost management strategies.
3Insights into consumer trends affecting sales.
4Details on competitive positioning in the health care market.
5Any guidance on future revenue growth expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Prestige Consumer Healthcare Inc. (PBH) operates in the health care sector, focusing on over-the-counter pharmaceuticals and consumer health products....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing costs and generating income.

Expecting $1.10

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market share and product offerings.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PBH Q1-2027 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.03%

Avg Stock Reaction

+2.05%

Last Quarter Recap

In Q4-2026, Prestige reported an EPS of $1.23, which was below analyst expectations. The stock reacted positively, increasing by 2.78% the following day despite the earnings miss.

Management Promises & Guidance

Focus on improving product lines and expanding market presence.
Commitment to cost management and operational efficiency.
Plans to enhance marketing strategies for better consumer engagement.

Expectations

Wall Street Expectations

Overall, Wall Street is cautiously optimistic about PBH's upcoming earnings, given the company's historical performance and market conditions.

Bull Case

If PBH beats EPS estimates and shows strong revenue growth, it could signal a recovery and renewed investor confidence, leading to a significant stock price increase.

Bear Case

Conversely, if the company misses expectations again, it may raise concerns about its operational efficiency and market competitiveness, potentially leading to a decline in stock value.

Key Metrics to Watch

Earnings Per Share (EPS)

Expecting $1.10

EPS is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue Growth

Not available

Revenue growth is crucial for assessing the company's ability to expand its market share and product offerings.

Market Share in OTC Products

Not available

Understanding market share will help gauge the company's competitive position in the health care market.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed $1.10 this quarter?

A strong EPS could indicate improved profitability and operational efficiency, which the market will closely watch.

What is the company's strategy for increasing market share in the OTC segment?

Insights into market share strategies will help investors assess the company's competitive position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate PBH's ability to adapt and innovate in the competitive OTC market, potentially leading to a stronger-than-expected performance.

Supporting Evidence

The company's recent investments in marketing and product development could yield better results than anticipated.

Historical data shows that PBH has a 63% EPS beat rate, suggesting a higher likelihood of positive surprises.

Options pricing indicates a significant expected move, which may reflect investor confidence in a turnaround.

Key Risk

If EPS comes in above $1.10, it could challenge the current cautious sentiment and validate the company's recovery narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a series of mixed earnings results, and the market is looking for signs of recovery.

Bull Confirmed If

An EPS of $1.10 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $1.00 would support the bear case, raising concerns about operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±12.18%

Historical Avg

±5.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±12.2% while PBH has averaged ±5.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

45.3%

Calls (0)P/C Ratio: 1.50Puts (10K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If PBH beats expectations, history suggests the stock could rise by an average of 5.17%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of around 3.16%, reflecting ongoing concerns about the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the OTC segment.
2Management's commentary on cost management strategies.
3Insights into consumer trends affecting sales.
4Details on competitive positioning in the health care market.
5Any guidance on future revenue growth expectations.